{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:14:28Z","timestamp":1781918068472,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2314-B-A49-044"],"award-info":[{"award-number":["MOST 111-2314-B-A49-044"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-A49-029"],"award-info":[{"award-number":["NSTC 112-2314-B-A49-029"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2314-B-075-025-MY2"],"award-info":[{"award-number":["NSTC113-2314-B-075-025-MY2"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112C-102"],"award-info":[{"award-number":["V112C-102"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113C-073"],"award-info":[{"award-number":["V113C-073"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113B-018"],"award-info":[{"award-number":["V113B-018"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40121-025-01126-1","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T09:13:15Z","timestamp":1743757995000},"page":"1027-1042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy"],"prefix":"10.1007","volume":"14","author":[{"given":"Chien","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chi","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Han","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hua","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chien","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ru","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Ling","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-7529","authenticated-orcid":false,"given":"Yi-Tsung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"1126_CR1","unstructured":"WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Licence: CC BY-NC-SA 3.0 IGO. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/376776\/9789240093461-eng.pdf?sequence=1."},{"key":"1126_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA, Infectious Diseases Society of America. Guidance on the treatment of antimicrobial resistant Gram-negative infections. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae403.","journal-title":"Clin Infect Dis"},{"key":"1126_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28:521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","volume":"55","author":"CL Sy","year":"2022","unstructured":"Sy CL, Chen PY, Cheng CW, Huang LJ, Wang CH, Chang TH, et al. Recommendations and guidelines for the treatment of infections due to multidrug-resistant organisms. J Microbiol Immunol Infect. 2022;55:359\u201386. https:\/\/doi.org\/10.1016\/j.jmii.2022.02.001.","journal-title":"J Microbiol Immunol Infect"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jgar.2022.09.012","volume":"31","author":"M Kempf","year":"2022","unstructured":"Kempf M, Arhin FF, Stone G, Utt E. Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019. J Glob Antimicrob Resist. 2022;31:239\u201347. https:\/\/doi.org\/10.1016\/j.jgar.2022.09.012.","journal-title":"J Glob Antimicrob Resist"},{"key":"1126_CR6","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:e00883-e917. https:\/\/doi.org\/10.1128\/AAC.00883-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1126_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66:163\u201371. https:\/\/doi.org\/10.1093\/cid\/cix783.","journal-title":"Clin Infect Dis"},{"key":"1126_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","volume":"68","author":"M Tumbarello","year":"2019","unstructured":"Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68:355\u201364. https:\/\/doi.org\/10.1093\/cid\/ciy492.","journal-title":"Clin Infect Dis."},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"e02320","DOI":"10.1128\/AAC.02320-19","volume":"64","author":"V Tsolaki","year":"2020","unstructured":"Tsolaki V, Mantzarlis K, Mpakalis A, Malli E, Tsimpoukas F, Tsirogianni A, et al. Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients. Antimicrob Agents Chemother. 2020;64:e02320-e2419. https:\/\/doi.org\/10.1128\/AAC.02320-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkaa503","volume":"76","author":"I Karaiskos","year":"2021","unstructured":"Karaiskos I, Daikos GL, Gkoufa A, Adamis G, Stefos A, Symbardi S, et al. Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. J Antimicrob Chemother. 2021;76:775\u201383. https:\/\/doi.org\/10.1093\/jac\/dkaa503.","journal-title":"J Antimicrob Chemother"},{"key":"1126_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00698-21","volume":"65","author":"L Chen","year":"2021","unstructured":"Chen L, Han X, Li Y, Li M. Assessment of mortality-related risk factors and effective antimicrobial regimens for the treatment of bloodstream infections caused by carbapenem-resistant Enterobacterales. Antimicrob Agents Chemother. 2021;65: e0069821. https:\/\/doi.org\/10.1128\/AAC.00698-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"1126_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab176","author":"M Tumbarello","year":"2021","unstructured":"Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing K. pneumoniae Infections: a retrospective observational multicenter study. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab176.","journal-title":"Clin Infect Dis."},{"key":"1126_CR13","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/jac\/dkab141","volume":"76","author":"SC Kuo","year":"2021","unstructured":"Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, et al. In vitro activity of imipenem\/relebactam, meropenem\/vaborbactam, ceftazidime\/avibactam, cefepime\/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. J Antimicrob Chemother. 2021;76:2071\u20138. https:\/\/doi.org\/10.1093\/jac\/dkab141.","journal-title":"J Antimicrob Chemother"},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10096-023-04733-3","volume":"43","author":"YT Lin","year":"2024","unstructured":"Lin YT, Chuang C, Chou SH, Juan CH, Yang TC, Kreiswirth BN, et al. Emergence of OXA-48-producing hypervirulent Klebsiella pneumoniae strains in Taiwan. Eur J Clin Microbiol Infect Dis. 2024;43:389\u201393. https:\/\/doi.org\/10.1007\/s10096-023-04733-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1126_CR15","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/jac\/dky204","volume":"73","author":"GG Stone","year":"2018","unstructured":"Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, et al. Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam phase III clinical trial programme. J Antimicrob Chemother. 2018;73:2519\u201323. https:\/\/doi.org\/10.1093\/jac\/dky204.","journal-title":"J Antimicrob Chemother"},{"key":"1126_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106517","volume":"59","author":"L Corbella","year":"2022","unstructured":"Corbella L, Bo\u00e1n J, San-Juan R, Fern\u00e1ndez-Ruiz M, Carretero O, Lora D, et al. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa. Int J Antimicrob Agents. 2022;59: 106517. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106517.","journal-title":"Int J Antimicrob Agents"},{"key":"1126_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615\u20138. https:\/\/doi.org\/10.1093\/cid\/ciw636.","journal-title":"Clin Infect Dis."},{"key":"1126_CR18","doi-asserted-by":"publisher","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","volume":"62","author":"RK Shields","year":"2018","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62:e02497-e2517. https:\/\/doi.org\/10.1128\/AAC.02497-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"e01637","DOI":"10.1128\/AAC.01637-19","volume":"63","author":"T Boulant","year":"2019","unstructured":"Boulant T, Jousset AB, Bonnin RA, Barrail-Tran A, Borgel A, Oueslati S, et al. A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment. Antimicrob Agents Chemother. 2019;63:e01637-19. https:\/\/doi.org\/10.1128\/AAC.01637-19.","journal-title":"Antimicrob Agents Chemother."},{"key":"1126_CR20","doi-asserted-by":"publisher","unstructured":"Khil PP, Dulanto Chiang A, Ho J, Youn JH, Lemon JK, Gea-Banacloche J, et al. Dynamic emergence of mismatch repair deficiency facilitates rapid evolution of ceftazidime-avibactam resistance in Pseudomonas aeruginosa acute infection. mBio. 2019;10:e01822\u201319. https:\/\/doi.org\/10.1128\/mBio.01822-19.","DOI":"10.1128\/mBio.01822-19"},{"issue":"24","key":"1126_CR21","doi-asserted-by":"publisher","first-page":"00648","DOI":"10.1016\/S1473-3099(24)00648-0","volume":"S1473\u20133099","author":"RK Shields","year":"2024","unstructured":"Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, et al. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2024;S1473\u20133099(24):00648. https:\/\/doi.org\/10.1016\/S1473-3099(24)00648-0.","journal-title":"Lancet Infect Dis"},{"key":"1126_CR22","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/jac\/dkz125","volume":"74","author":"M Papadimitriou-Olivgeris","year":"2019","unstructured":"Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou ED, et al. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime\/avibactam. J Antimicrob Chemother. 2019;74:2051\u20134. https:\/\/doi.org\/10.1093\/jac\/dkz125.","journal-title":"J Antimicrob Chemother"},{"key":"1126_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"1126_CR24","unstructured":"Clinical and Laboratory Standards Institute M100-S32. Performance standards for antimicrobial susceptibility testing: 32nd informational supplement. CLSI, Wayne, PA. 2022."},{"key":"1126_CR25","doi-asserted-by":"publisher","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, et al. The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM Study. Open Forum Infect Dis. 2019;6:ofz522. https:\/\/doi.org\/10.1093\/ofid\/ofz522.","DOI":"10.1093\/ofid\/ofz522"},{"key":"1126_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","volume":"12","author":"A Soriano","year":"2023","unstructured":"Soriano A, Montravers P, Bassetti M, Klyasova G, Daikos G, Irani P, et al. The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM Study. Infect Dis Ther. 2023;12:891\u2013917. https:\/\/doi.org\/10.1007\/s40121-023-00762-9.","journal-title":"Infect Dis Ther"},{"key":"1126_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107244","volume":"64","author":"SH Chou","year":"2024","unstructured":"Chou SH, Chuang C, Juan CH, Ho YC, Liu SY, Chen L, et al. Mechanisms and fitness of ceftazidime\/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan. Int J Antimicrob Agents. 2024;64: 107244. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107244.","journal-title":"Int J Antimicrob Agents"},{"key":"1126_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jgar.2023.03.012","volume":"33","author":"A Oliva","year":"2023","unstructured":"Oliva A, Al Ismail D, Arcari G, Miele MC, Casali E, Sacco F, et al. Ceftazidime\/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations. J Glob Antimicrob Resist. 2023;33:321\u20137. https:\/\/doi.org\/10.1016\/j.jgar.2023.03.012.","journal-title":"J Glob Antimicrob Resist"},{"key":"1126_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/1120009X.2022.2031471","volume":"34","author":"G Bianco","year":"2022","unstructured":"Bianco G, Boattini M, Comini S, Iannaccone M, Casale R, Allizond V, et al. Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in northern Italy (2019\u20132021): emergence of complex resistance phenotypes. J Chemother. 2022;34:302\u201310. https:\/\/doi.org\/10.1080\/1120009X.2022.2031471.","journal-title":"J Chemother"},{"key":"1126_CR30","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","volume":"64","author":"SE Boyd","year":"2020","unstructured":"Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64:e00397-e420. https:\/\/doi.org\/10.1128\/AAC.00397-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1126_CR31","unstructured":"Centers for Disease Control, R.O.C (Taiwan). Taiwan healthcare-associated infection and antimicrobial resistance surveillance report. Available At: https:\/\/www.cdc.gov.tw\/Category\/Page\/tx7G1t-G3lyodZ8m8uoYMA. Accessed 23 July 2024."},{"key":"1126_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02342-6","author":"R Casale","year":"2024","unstructured":"Casale R, Boattini M, Comini S, Bastos P, Corcione S, De Rosa FG, et al. Clinical and microbiological features of positive blood culture episodes caused by non-fermenting Gram-negative bacilli other than Pseudomonas and Acinetobacter species (2020\u20132023). Infection. 2024. https:\/\/doi.org\/10.1007\/s15010-024-02342-6.","journal-title":"Infection"},{"key":"1126_CR33","doi-asserted-by":"publisher","first-page":"e00590","DOI":"10.1128\/AAC.00590-18","volume":"62","author":"A Van Dalem","year":"2018","unstructured":"Van Dalem A, Herpol M, Echahidi F, Peeters C, Wybo I, De Wachter E, et al. In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam. Antimicrob Agents Chemother. 2018;62:e00590-e618. https:\/\/doi.org\/10.1128\/AAC.00590-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1126_CR34","doi-asserted-by":"publisher","first-page":"e02213","DOI":"10.1128\/AAC.02213-17","volume":"62","author":"PD Tamma","year":"2018","unstructured":"Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam. Antimicrob Agents Chemother. 2018;62:e02213-e2217. https:\/\/doi.org\/10.1128\/AAC.02213-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1126_CR35","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/jac\/dky558","volume":"74","author":"G Spoletini","year":"2019","unstructured":"Spoletini G, Etherington C, Shaw N, Clifton IJ, Denton M, Whitaker P, et al. Use of ceftazidime\/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series. J Antimicrob Chemother. 2019;74:1425\u20139. https:\/\/doi.org\/10.1093\/jac\/dky558.","journal-title":"J Antimicrob Chemother"},{"key":"1126_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01447-21","volume":"59","author":"HK Huse","year":"2021","unstructured":"Huse HK, Lee MJ, Wootton M, Sharp SE, Traczewski M, LiPuma JJ, et al. Evaluation of antimicrobial susceptibility testing methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from cystic fibrosis patients. J Clin Microbiol. 2021;59: e0144721. https:\/\/doi.org\/10.1128\/JCM.01447-21.","journal-title":"J Clin Microbiol"},{"key":"1126_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/QCO.0000000000000977","volume":"36","author":"D Koulenti","year":"2023","unstructured":"Koulenti D, Vandana KE, Rello J. Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains. Curr Opin Infect Dis. 2023;36:545\u201354. https:\/\/doi.org\/10.1097\/QCO.0000000000000977.","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"1126_CR38","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00432-021-03741-0","volume":"148","author":"V Himmelsbach","year":"2022","unstructured":"Himmelsbach V, Knabe M, Ferstl PG, Peiffer KH, Stratmann JA, Wichelhaus TA, et al. Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2022;148(6):1465\u201372. https:\/\/doi.org\/10.1007\/s00432-021-03741-0.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1126_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/cncr.31045","volume":"124","author":"S Scheich","year":"2018","unstructured":"Scheich S, Lindner S, Koenig R, Reinheimer C, Wichelhaus TA, Hogardt M, et al. Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Cancer. 2018;124(2):286\u201396. https:\/\/doi.org\/10.1002\/cncr.31045.","journal-title":"Cancer"},{"key":"1126_CR40","doi-asserted-by":"publisher","first-page":"32665","DOI":"10.1038\/srep32665","volume":"6","author":"PF Wu","year":"2016","unstructured":"Wu PF, Chuang C, Su CF, Lin YT, Chan YJ, Wang FD, et al. High minimum inhibitory concentration of imipenem as a predictor of fatal outcome in patients with carbapenem non-susceptible Klebsiella pneumoniae. Sci Rep. 2016;6:32665. https:\/\/doi.org\/10.1038\/srep32665.","journal-title":"Sci Rep"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01126-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T08:23:54Z","timestamp":1747383834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01126-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01126-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chien Chuang, Tzu-Chi Kao, Chih-Han Juan, Sheng-Hua Chou, Yu-Chien Ho, Szu-Yu Liu, Yi-Ru Huang, Hsiang-Ling Ho, and Yi-Tsung Lin have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institution Review Board of Taipei Veterans General Hospital (Taipei, Taiwan) (registration no. 2021\u201312-015CC). Informed consent was waived due to the retrospective study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}